BioInvent International

Declaration of Voting Results & Voting Rights Announcements • Apr 30, 2014

PRESS RELEASE 30 April 2014

Change in the number of shares and votes in BioInvent International AB (publ)

BioInvent International AB (publ) (OMXS:BINV) today announced that the company's total number of shares as per 30 April 2014 amounts to 112,790,050 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from the rights issue of 21,253,662 shares with preferential right for the company's shareholders and the directed new share issue of 6,521,739 additional shares, both announced on 24 February 2014.

-- END –

To the editors:

About BioInvent

BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Les Laboratoires Servier and Mitsubishi Tanabe Pharma. More information is available at www.bioinvent.com.

For further information, please contact:

Michael Oredsson President and CEO +46 (0)46 286 85 67 +46 (0)707 16 89 30 michael.oredsson@bioinvent.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263 Visiting address: Sölvegatan 41 Mailing address: 223 70 LUND Phone: +46 (0)46 286 85 50 info@bioinvent.com www.bioinvent.com

Information disclosed in this press release is provided herein pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8.40 a.m. CET, on 30 April, 2014.